Seven Fleet Capital Management LP Invests $1.03 Million in Geron Corporation $GERN

Seven Fleet Capital Management LP acquired a new stake in Geron Corporation (NASDAQ:GERN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 777,880 shares of the biopharmaceutical company’s stock, valued at approximately $1,027,000. Geron makes up approximately 0.8% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 23rd largest holding.

Other institutional investors have also modified their holdings of the company. RA Capital Management L.P. raised its holdings in Geron by 5.6% in the fourth quarter. RA Capital Management L.P. now owns 63,771,366 shares of the biopharmaceutical company’s stock valued at $84,178,000 after buying an additional 3,392,000 shares during the period. Vanguard Group Inc. boosted its position in Geron by 3.6% in the 4th quarter. Vanguard Group Inc. now owns 35,660,969 shares of the biopharmaceutical company’s stock valued at $47,072,000 after buying an additional 1,237,844 shares during the last quarter. State Street Corp boosted its holdings in Geron by 0.9% in the fourth quarter. State Street Corp now owns 26,867,322 shares of the biopharmaceutical company’s stock valued at $35,465,000 after purchasing an additional 248,508 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Geron by 8.0% during the 2nd quarter. Vestal Point Capital LP now owns 23,775,000 shares of the biopharmaceutical company’s stock valued at $33,523,000 after buying an additional 1,769,660 shares during the last quarter. Finally, Eversept Partners LP grew its holdings in Geron by 40.2% during the 4th quarter. Eversept Partners LP now owns 17,659,983 shares of the biopharmaceutical company’s stock worth $23,311,000 after acquiring an additional 5,060,981 shares in the last quarter. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, May 26th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Geron currently has a consensus rating of “Hold” and a consensus target price of $2.50.

Geron Price Performance

Shares of NASDAQ GERN opened at $1.26 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.78 and a quick ratio of 4.96. Geron Corporation has a 1-year low of $1.04 and a 1-year high of $2.01. The business’s fifty day moving average price is $1.39 and its two-hundred day moving average price is $1.44. The firm has a market capitalization of $808.32 million, a PE ratio of -11.45 and a beta of 0.60.

Geron (NASDAQ:GERN) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02. Geron had a negative return on equity of 23.31% and a negative net margin of 35.48%.The firm had revenue of $51.84 million for the quarter, compared to the consensus estimate of $50.59 million. On average, research analysts expect that Geron Corporation will post -0.02 EPS for the current year.

Geron Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.